Combined administration of glutamine and growth hormone synergistically reduces bacterial translocation in sepsis.
We investigated the combined effect of glutamine (GLN) and growth hormone (GH) on bacterial translocation (BT) in sepsis. After single intraperitoneal injection of lipopolysaccharide (10 mg/kg), 48 rats were divided randomly into four groups of 12 animals each: the control group received chow orally; the GLN group received chow plus 10% GLN; GH group received chow plus GH; and the GLN/GH group received chow, 10% GLN, and GH. Twenty-four and 96 hr later, rats were sacrificed. Portal blood culture, bacterial colony counts of cultured mesenteric lymph nodes, mucosal thickness, malondialdehyde (MDA), and glutathione (GSH) levels in the gut mucosa were measured. There was no significant change of the rate of portal blood culture between all treatment groups at 24 and 96 hr. At 24 hr, the rats receiving combined treatment of GLN and GH showed lower bacterial colony counts and mucosal MDA levels than the control rats, and higher mucosal GSH levels than the control and GLN-treated rats. At 96 hr, rats treated with both GLN and GH exhibited lower bacterial colony counts and mucosal MDA levels, and higher mucosal thickness and GSH levels than control, GLN, or GH-treated rats. This study suggests that the combination of GLN and GH may synergistically reduce BT over time in sepsis.
Jung
Sung-Eun
SE
Department of Surgery, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea. suhgil@snu.ac.kr
Youn
Yeo-Kyu
YK
Lim
Yong-Su
YS
Song
Hyoung-Gon
HG
Rhee
Joong-Eui
JE
Suh
Gil-Joon
GJ
D000818:Animals; D016470:Bacteremia / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control; D018988:Bacterial Translocation / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D019446:Endotoxemia / Q000188:drug therapy* / Q000382:microbiology; D004926:Escherichia coli / Q000302:isolation & purification*; D005973:Glutamine / Q000494:pharmacology* / Q000627:therapeutic use; D005978:Glutathione / Q000032:analysis; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D007082:Ileum / Q000382:microbiology / Q000473:pathology; D007413:Intestinal Mucosa / Q000382:microbiology / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D018805:Sepsis / Q000382:microbiology / Q000517:prevention & control*; D013047:Specific Pathogen-Free Organisms
D011994:Recombinant Proteins; D005973:Glutamine; D019382:Human Growth Hormone; D005978:Glutathione